Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

431

Participants

Timeline

Start Date

October 28, 2009

Primary Completion Date

September 2, 2016

Study Completion Date

April 10, 2020

Conditions
Fallopian Tube CarcinomaFallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous NeoplasmFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Brenner TumorOvarian CarcinomaOvarian CarcinosarcomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Seromucinous TumorOvarian Serous AdenocarcinomaOvarian Transitional Cell CarcinomaOvarian Undifferentiated CarcinomaPrimary Peritoneal CarcinomaPrimary Peritoneal Serous AdenocarcinomaStage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIA Ovarian Cancer AJCC V6 and v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIB Ovarian Cancer AJCC v6 and v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage IIC Ovarian Cancer AJCC v6 and v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IP

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV or IP

DRUG

Veliparib

Given PO

Trial Locations (23)

10065

Memorial Sloan Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

19111

Fox Chase Cancer Center, Philadelphia

21237

MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

30912

Augusta University Medical Center, Augusta

35233

University of Alabama at Birmingham Cancer Center, Birmingham

43210

Ohio State University Comprehensive Cancer Center, Columbus

43214

Riverside Methodist Hospital, Columbus

44106

Case Western Reserve University, Cleveland

44109

MetroHealth Medical Center, Cleveland

44111

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44195

Cleveland Clinic Foundation, Cleveland

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53792

University of Wisconsin Hospital and Clinics, Madison

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

80045

University of Colorado Hospital, Aurora

02905

Women and Infants Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT00989651 - Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter